- Results from phase 2 STRONG-SCD study using olinciguat for the treatment of patients with sickle cell disease expected before the end of 2020.
- The global sickle cell disease market is expected to reach $5.5 billion by 2023.
- IW-6463 is being used to target patients with Alzheimer's disease with vascular pathology (ADv) and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS).
- Results from a phase 1 study using IW-6463 to treat patients with central nervous system disorders are expected any day now in October 2020.
For further details see:
Cyclerion Is A Speculative Biotech With A Few Catalysts Approaching